Clinical Trial

CD19-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory B-Lineage Leukaemia / Lymphoma - A Feasibility Protocol

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated March 9, 2023 (before its estimated December 2025 completion). Its status may not reflect the trial's current state.
Summary
The purpose of this study is to describe feasibility of delivering point-of-care manufactured CD19-directed CAR T-cell therapy to patients with relapsed/ refractory B-lineage leukaemia/ lymphoma.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2022-12-04.
Trial Details
NCT Number NCT05648019
Lead Sponsor KK Women's and Children's Hospital
Collaborators: Singapore General Hospital
Conditions Lymphoblastic Leukemia, Lymphoblastic Leukemia in Children, Lymphoblastic Leukemia, Acute Adult, B-cell Acute Lymphoblastic Leukemia, Large B-cell Lymphoma, CAR
Enrollment 40 participants
Start Date 2022-03-15
Primary Completion 2025-12 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2023-03-09